Stocks
Latest stock market news — earnings, indices, equities, and corporate events explained for retail investors.
1657 articles in Stocks — page 82 of 139
StocksRussian Stocks Rise as Oil & Gas Sector Boosts Market
Russian equities closed higher, driven by gains in key sectors like Oil & Gas and Manufacturing.
StocksRocket Lab Stock Rises 2% After Major Hypersonic Contract Win
Rocket Lab shares increased 2% after securing a $190 million contract for hypersonic test flights.
StocksAfter-Hours Stock Movements: Micron, Five Below, and DLocal Limited
Micron's stock dips despite strong earnings, while Five Below and DLocal see gains after positive reports.
StocksU.S. Stocks Decline as Dow Jones Hits 3-Month Low
U.S. stock markets closed lower, with the Dow Jones down 1.64%, driven by losses in key sectors.
StocksBrazilian Stocks Decline as Key Sectors Struggle
Brazil's stock market closed lower, driven by declines in major sectors including Basic Materials and Financials.
StocksQnity Stock Gains 2% After NVIDIA Partnership Announcement
Qnity shares rose 2% following a collaboration with NVIDIA to enhance AI-driven materials research.
StocksSwarmer Inc Completes $17.25 Million IPO on NASDAQ
Swarmer Inc has successfully closed its IPO, raising $17.25 million to enhance its drone software operations.
StocksKraft Heinz and Unilever Explore Merger of Food Brands
Kraft Heinz and Unilever recently discussed merging their food brands, but talks have ended.
StocksZillow Shares Rise as Compass Drops Lawsuit
Zillow's stock increases after Compass ends its lawsuit over home-listing rules.
StocksFigma Shares Drop as Google Labs Enhances AI Design Tool Stitch
Figma's stock fell 8.8% after Google Labs upgraded its AI design tool, Stitch, raising competition concerns.
StocksKey Economic Data Releases to Impact Markets on Thursday
Traders brace for important economic indicators on March 19, 2026, affecting housing and labor markets.
StocksArtelo Biosciences Shares Soar After Glaucoma Study Agreement
Artelo Biosciences stock rises 32.9% following a study agreement to test its glaucoma drug candidate.